PCT Patent Approved for CinGx™ to Treat and Prevent Diabetes, Alzheimer's and Dementias

CinGx™ and Type 3 Diabetes

Jun 08, 2010, 08:30 ET from Allegiance Equity Corporation

TORONTO, June 8 /PRNewswire-FirstCall/ -- There is currently no cure for Diabetes, Alzheimer's and Dementia but they can be treated and prevented. Allegiance Equity developed CinGx™ as a safe and effective treatment for these diseases. The incidence of these diseases and associated costs continue to soar out of control and afflict the world-wide population. Current treatments are not satisfactory and many have side effects.

CinGx™ controls glucose metabolism improves brain function and a healthy cognitive system. It contains two purified and concentrated natural extracts that act synergistically to control glucose metabolism, improve brain function, and minimize the risk of developing dementia, Alzheimer's and diabetes.

CinGx™ is effective against recently discovered 'type 3' diabetes resulting from lower than normal levels of newly detected brain insulin, causing Alzheimer's disease. Diabetes increases the risk of Alzheimer's disease by up to 65%.

CinGx™ is a natural proprietary OTC food additive and meets regulatory requirements in North America.

Health Benefits of CinGx™ include





Reduces Blood Sugar

Reduces Cholesterol


Reduces Triglycerides

Improves Memory


Improves Cognitive Function

Improves Energy


Improves Mental Well Being



Anti-Oxidant for Anti-Aging




CinGx AN EVOLUTION ON FUNCTIONAL FOODS

CinGx ™ provides exciting new Health Benefits in a multitude of food products resulting in distinct competitive advantages of

  • Increase demand
  • Higher Prices
  • Increased Margins and Profits

Applications include beverages, coffee, tea, sweeteners, diet foods, meal replacement, yogurt vitamins and diabetic products etc.

Demand for functional foods with proven Health Benefits is the fastest growing sector of the food industry.

Several manufacturers have developed new products containing CinGx™ to market.

Patent Approvals CinGx™

International Patent Applications have been issued and published for CinGx™ recognizing the health claims for TYPE 3 DIABETES.

About Allegiance

Allegiance develops IP for dermatology, diabetic, and related cardiovascular central nervous diseases where existing products fail to meet the needs of patients. And obtains regulatory approval in North America markets.

Allegiance is licensing its extensive portfolio of regulatory approvals and patents internationally.

Symbol:  ANQ (TSX V)

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY FOR THIS PRESS RELEASE, WHICH HAS BEEN PREPARED BY MANAGEMENT.

SOURCE Allegiance Equity Corporation